Join the Network
Twitter Youtube
info@skincanada.org
Menu

Inflammatory Skin Diseases

  1. Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Rademaker M, Fomina D, Gutermuth J, Ahn J, Valenzuela F, Ameen M, Steinhoff M, Kirchhof MG, Lio P, Wollenberg A. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. Jul 11 2024.https://www.ncbi.nlm.nih.gov/pubmed/38989857
  2. Wheeler KE, Chu DK, Schneider L. Updated Guidelines for Atopic Dermatitis-AAAAI/ACAAI Joint Task Force. JAMA Pediatr. Jul 8 2024.https://www.ncbi.nlm.nih.gov/pubmed/38976275
  3. Chu X, Wang J, Ologundudu L, Brignardello-Petersen R, Guyatt GH, Oykhman P, Bernstein JA, Saini SS, Beck LA, Waserman S, Moellman J, Khan DA, Ben-Shoshan M, Baker DR, Oliver ET, Sheikh J, Lang D, Mathur SK, Winders T, Eftekhari S, Gardner DD, Runyon L, Asiniwasis RN, Cole EF, Chan J, Wheeler KE, Trayes KP, Tran P, Chu DK. Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Allergy Clin Immunol Pract. Jul 2024;12(7):1879-1889 e1878.https://www.ncbi.nlm.nih.gov/pubmed/38642709
  4. Ushcatz I, Zhao HJ, Tadrous M, Aoki V, Chang AY, Dlova N, Merilleno ASP, Drucker AM. Association of Countries’ Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization. Dermatitis. Jul 3 2024.https://www.ncbi.nlm.nih.gov/pubmed/38959123
  5. Li K, Bouadi N, Jeremian R, Bi WG, Piguet V, Croitoru DO. A Comparative Analysis of Hidradenitis Suppurativa and Acne Inversa Webpages. Clin Exp Dermatol. Jul 3 2024.https://www.ncbi.nlm.nih.gov/pubmed/38959433
  6. Korman NJ, Warren RB, Bagel J, Armstrong AW, Gooderham M, Strober B, Thaci D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli L, Kisa RM, Banerjee S, Blauvelt A. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. J Dermatolog Treat. Dec 2024;35(1):2371045.https://www.ncbi.nlm.nih.gov/pubmed/38945549
  7. Gooderham MJ, de Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL, Tsianakas A, Kerkmann U, Feeney C, Romero W. Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations. Dermatol Ther (Heidelb). Jul 2 2024.https://www.ncbi.nlm.nih.gov/pubmed/38954384
  8. Guenther L, Turchin I, Vender R, Albrecht LE, Maari C, Yanofsky H, Prajapati VH. Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis. Dermatol Ther (Heidelb). Jun 25 2024.https://www.ncbi.nlm.nih.gov/pubmed/38916719
  9. Seigel L, Shoaib S, Maughn K, Foster M, Shah S, Batchu L, Wittstock K, Alexis A. Health disparities in psoriasis: geographic barriers to access in the United States. J Dermatolog Treat. Dec 2024;35(1):2365820.https://www.ncbi.nlm.nih.gov/pubmed/38914420
  10. Sampath AJ, Westerkam LL, Blum FR, Alhusayen R, Bechara FG, Caffrey J, Carmona-Rivera C, Chandran NS, George R, Goldberg SR, Gudjonsson JE, Hansen SL, Ingram JR, Kirby B, Marzano AV, Matusiak L, Orgill DP, Prens E, van der Zee HH, van Straalen KR, Zouboulis CC, Byrd AS, Frew JW, Anne Lowes M, Naik HB, Sokumbi O, Mi QS, Miedema JR, Googe PB, Sayed CJ. Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens. The Journal of investigative dermatology. Jun 18 2024.https://www.ncbi.nlm.nih.gov/pubmed/38901775
  11. Chu AWL, Rayner DG, Chu X, Chen L, Dong AYH, Waserman S, Baker DR, Sheikh J, Moellman J, Lang DM, Ben-Shoshan M, Mathur SK, Beck LA, Khan DA, Oliver ET, Asiniwasis RN, Chan J, Cole EF, Trayes KP, Frazier WT, Runyon L, Wheeler KE, Eftekhari S, Gardner DD, Winders T, Bernstein JA, Saini SS, Chu DK. Topical corticosteroids for hives and itch (urticaria): systematic review and Bayesian meta-analysis of randomized trials. Ann Allergy Asthma Immunol. Jun 18 2024.https://www.ncbi.nlm.nih.gov/pubmed/38901542
  12. Armstrong AW, Alexis AF, Blauvelt A, Silverberg JI, Feeney C, Levenberg M, Chan G, Zhang F, Fostvedt L. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). Jun 19 2024.https://www.ncbi.nlm.nih.gov/pubmed/38896380
  13. Vu D, Park M, Alhusayen R. Efficacy of Moxifloxacin as a Mono-antibiotic Therapy for Hidradenitis Suppurativa: A Retrospective Cohort Study. J Am Acad Dermatol. May 31 2024.https://www.ncbi.nlm.nih.gov/pubmed/38825077
  14. Jeremian R, Malinowski A, Oh ES, Gooderham M, Sibbald C, Yeung J, Asai Y, Piguet V, Jack CS. Epigenetic and biological age acceleration in children with atopic dermatitis. J Allergy Clin Immunol Glob. Aug 2024;3(3):100275.https://www.ncbi.nlm.nih.gov/pubmed/38826624
  15. Baldwin H, Gold LS, Harper JC, Alexis AF, Callender VD, Kircik L, Guenin E, Eichenfield LF. Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants. J Drugs Dermatol. Jun 1 2024;23(6):394-402.https://www.ncbi.nlm.nih.gov/pubmed/38834226
  16. Garcia-Romero MT, Brandling-Bennett HA, Pope E, Sibbald C, Medina-Vera I, Elizalde-Jimenez IG, Chiu YE. Responsiveness to Change of the Morphea Activity Measure in Pediatric Patients. JAMA Dermatol. Jun 5 2024.https://www.ncbi.nlm.nih.gov/pubmed/38837147
  17. Kircik LH, Stein Gold L, Gold M, Weiss JS, Harper JC, Del Rosso JQ, Bunick CG, Bhatia N, Tanghetti EA, Eichenfield LF, Baldwin H, Draelos ZD, Callender VD, Han G, Gooderham MJ, Sadick N, Lupo MP, Lain ET, Werschler WP. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis. Dermatol Ther (Heidelb). May 9 2024.https://www.ncbi.nlm.nih.gov/pubmed/38724841
  18. Alexis A, Del Rosso JQ, Forman S, Martorell A, Browning J, Laquer V, Desai SR, York JP, Chavda R, Dhawan S, Moore AY, Stein-Gold L. Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation. Int J Dermatol. Apr 29 2024.https://www.ncbi.nlm.nih.gov/pubmed/38685118
  19. Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, Silverberg JI, Siegfried EC, Kuligowski ME, Venturanza ME, Kallender H, Ren H, Paller AS. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. Am J Clin Dermatol. May 2 2024.https://www.ncbi.nlm.nih.gov/pubmed/38698175
  20. Tyring S, Moore A, Morita A, Hong HC, Song IH, Eccleston J, Levy G, Mohamed MF, Qian Y, Wu T, Pan A, Hew K, Papp KA. Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial. Clin Exp Dermatol. May 3 2024.https://www.ncbi.nlm.nih.gov/pubmed/38699939
  21. Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Salle D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI. Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). May 3 2024.https://www.ncbi.nlm.nih.gov/pubmed/38700646
  22. Molnar BA, Levin L, Yun D, Morel K, Wiss K, Wieser J, Ward C, Trice H, Garcia-Romero MT, Stephenson A, Provost A, Price HN, Perman MJ, Moxon M, Moeves B, McCuaig CC, McCarthy C, Lucky AW, Levy ML, Lee M, Lara-Corrales I, Henner N, Halliburton N, Griffith E, Gorell E, Glick S, Eichenfield L, Collins C, Bruckner AL, Boulrice B, Bayliss S, Badger K, Paller AS. Inpatient Management of Epidermolysis Bullosa: Consensus-Based Hands-On Instructions for Neonates and Post-Neonates. J Am Acad Dermatol. Apr 9 2024.https://www.ncbi.nlm.nih.gov/pubmed/38604489
  23. Park M, Vu D, Alhusayen R. Trimethoprim-Sulfamethoxazole as a Mono-Antibiotic Therapy for Hidradenitis Suppurativa. J Cutan Med Surg. Apr 9 2024:12034754241247520.https://www.ncbi.nlm.nih.gov/pubmed/38591774
  24. Panel AAJADG, Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O’Brien M, Ong PY, Silverberg JI, Spergel JM, Wang J, Wheeler KE, Guyatt GH, Patient Groups: Global Parents for Eczema R, Capozza K, National Eczema A, Begolka WS, Evidence in Allergy G, Chu AWL, Zhao IX, Chen L, Oykhman P, Bakaa L, Parameters AAJTFoP, Golden D, Shaker M, Bernstein JA, Greenhawt M, Horner CC, Lieberman J, Stukus D, Rank MA, Wang J, Ellis A, Abrams E, Ledford D, Chu DK. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. Mar 2024;132(3):274-312.https://www.ncbi.nlm.nih.gov/pubmed/38108679
  25. Wan V, Habibi A, Abdi P, Mukovozov I, Asiniwasis RN, Maibach HI. Systematic scoping review on the barriers to access of biologics in moderate-to-severe adult atopic dermatitis. Australas J Dermatol. Mar 4 2024.https://www.ncbi.nlm.nih.gov/pubmed/38439194
  26. Zabihi H, Shojaei D, Seigel K, Al-Dehneem R, Piguet V, Croitoru DO. Evaluating the Clinical Utility of Sulfasalazine in the Treatment of Pyoderma Gangrenosum: A Systematic Review. J Cutan Med Surg. Mar 10 2024:12034754241238713.https://www.ncbi.nlm.nih.gov/pubmed/38462891
  27. Metko D, Mehta S, Piguet V. Cannabis Usage Among Patients With Hidradenitis Suppurativa: A Scoping Review. J Cutan Med Surg. Mar 10 2024:12034754241238719.https://www.ncbi.nlm.nih.gov/pubmed/38462895
  28. Riaz S, Emam S, Wang T, Gniadecki R. Negative impact of comorbidities on all-cause mortality of psoriasis patients is partially alleviated by biologic treatment: A real-world, case-control study. J Am Acad Dermatol. Feb 20 2024.https://www.ncbi.nlm.nih.gov/pubmed/38387852
  29. Ameen M, Alhusayen R, Brandi H, Bogelund M, Jensen HH, Reitzel SB, Thyssen JP. Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis. Acta Derm Venereol. Feb 21 2024;104:adv24339.https://www.ncbi.nlm.nih.gov/pubmed/38380974
  30. Gladman DD, Chandran V, Rosen CF, Rohekar S, Boyd T, Eder L, Rahman P, Dutz J, Chan J, Haydey RP, Barac S, Laliberte MC, Girard T, Fournier PA, Sutton M, Pereira D, Chim T, Coupal L, Choquette D. Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA). J Rheumatol. Feb 15 2024.https://www.ncbi.nlm.nih.gov/pubmed/38359937
  31. Brandling-Bennett HA, Arkin LM, Chiu YE, Hebert AA, Callen JP, Castelo-Soccio L, Co DO, Cordoro KM, Curran ML, Dalrymple AM, Flohr C, Gordon KB, Hanna D, Irvine AD, Kim S, Kirkorian AY, Lara-Corrales I, Lindstrom J, Paller AS, Reyes M, Begolka WS, Tom WL, Van Voorhees AS, Vleugels RA, Lee LW, Davies O, Siegfried EC. Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients. J Am Acad Dermatol. Feb 9 2024.https://www.ncbi.nlm.nih.gov/pubmed/38342248
  32. Deodhar A, Blauvelt A, Lebwohl M, Feely M, Kronbergs A, Eberhart N, Zhu D, Inman E, Grace E, Holzkaemper T, Rahman P, Marzo-Ortega H, Papp KA, Merola JF, Gottlieb AB, Schwartzman S. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis research & therapy. Feb 12 2024;26(1):49.https://www.ncbi.nlm.nih.gov/pubmed/38347650